TABLE 1.
Patient characteristics
| Vitamin D group (N = 17) | Placebo group (N = 15) | p‐value | |
|---|---|---|---|
| Age (y), mean (SD) | 38.3 (8.17) | 38.5 (7.32) | .91 |
| EDSS a score, median (95% Cl) | 2.0 (1.5–3.0) | 1.5 (1.0–3.0) | .16 |
| Body mass index, mean (SD) | 26.2 (5.15) | 24.72 (4.96) | .42 |
| Immunomodulatory treatment a , N | 17 | 15 | .60 |
| Smoking, N | 8 | 4 | .99 |
| 25‐hydroxyvitamin D (nmol/L), mean (SD) | 52.2 (16.86) | 58.5 (20.71) | .37 |
| 25 FW b , mean (SD) | 4.87 (1.27) | 4.90 (1.75) | .67 |
| NfL (pg/mL), median (95% CI) | 12.44 (9.9–16.8) | 11.86 (8.5–14.8) | .47 |
| T2 BOD, mean (SD) | 8,452 (10,698) | 8,702 (8,743) | |
| Median (95% Cl) | 3,465 (2224–12016) | 6,421 (2187–11272) | .71 |
| No. of Gd‐enhancing lesions, mean (SD) | 0.29 (0.69) | 0.20 (0.56) | .89 |
| T1 enhancing lesion volume (mm2), mean (SD) | 30.47 (71.3) | 30.20 (89.12) | .93 |
| Disease duration (year), mean | |||
| From onset of symptoms | 7.79 (6.94) | 7.31 (5.92) | .75 |
| From diagnosis | 6.08 (6.22) | 4.96 (4.48) | .79 |
| Annual relapse rate b , median (95% Cl) | 0.49 (0.31–0.66) | 0.52 (0.33–0.7) | .67 |
| Interferon therapy (years) Mean, SD | 2.78 | 2.61 | .67 |
All patients received interferon β‐1b therapy and had an interferon response measured by MxA test. Annual relapse rate was from 2 years before the study onset.
Abbreviations: BOD, burden of disease, mm3; NfL, neurofilament light in serum.
a
EDSS, Kurtzke's Expanded Disability Status Scale.
b
25 FW, timed 25‐foot walk test in seconds.